Gene therapy for prostate cancer

Gene Therapy

Volumn 3, Issue 10, 1996, Pages 845-852

  Hrouda, D ^a   Dalgleish, A G ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Cytokines; Gene therapy; Prostate cancer

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; GENE INSERTION; GENE THERAPY; HUMAN; MALE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; CANCER VACCINES; GENE THERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS;

ANIMALIA;

EID: 0029862797     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (87)

1. Boring CC et al. Cancer statistics, 1994. Ca. a Cancer Journal for Clinicians 1994; 44: 7-26
2. Jensen OM et al Cancer in the European Community and its member states. Eur J Cancer 1990; 26: 1167-1256 (published erratum appears in Eur J Cancer 1991; 27: 1717) (see comments)
3. Carter BS, Carter HB, Isaacs JT. Epidemiologie evidence regarding predisposing factors to prostate cancer. Prostate 1990; 16: 187-197.
4. Huggins C, Hodges C. Studies on prostatic cancer. I The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-297.
5. Crawford ED et al. Leuprolide with and without flutamide in advanced prostate cancer. Cancer 1990; 66 (Suppl): 1039-1044.
6. Burnet FM. Immunological Surveillance. Pergamon Press: Oxford, 1970.
7. Vesalainen S et al. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994; 30A: 1797-1803.
8. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991; 49: 281-355.
9. Sanda MG et al. Molecular characterization of defective antigen processing in human prostate cancer (see comments). J Natl Cancer Inst 1995; 87: 280-285.
10. Blades RA et al. Loss of HLA class I expression in prostate cancer implications for immunotherapy. Urology 1995; 46: 681-686; Discussion 686-687.
11. Corman JM et al. Prostate specific antigenic peptides induce T cell proliferation in vitro: a model for the development of prostate specific tumor vaccines. J Urol 1996; 155: 528a (Abstr. 870).
12. Chen ME et al. PAGE and GAGE 7 are novel genes expressed in the LNCaP prostatic carcinogenesis model that share homology with melanoma-associated antigens. J Urol 1996; 155: 624a (Abstr. 1251).
13. Brenner PC et al. TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49 (see comments). J Urol 1995; 153: 1575-1579.
14. Beckett ML et al. Monoclonal antibody PD41 recognizes an antigen restricted to prostate adenocarcinomas. Cancer Res 1991; 51: 1326-1333.
15. Beckett ML, Wright GL Jr. Characterization of a prostate carcinoma mucin-like antigen (PMA). Int J Cancer 1995, 62: 703-710.
16. Wright GL Jr et al. A novel prostate carcinoma-associated glycoprotein complex (PAC) recognized by monoclonal antibody TURP-27. Int J Cancer 1991; 47: 717-725.
17. Shurbaji MS et al. Expression of oncogenic antigen 519 (OA-519) in prostate cancer is a potential prognostic indicator. Am J Clin Pathol 1992; 97: 686-691
18. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Ann Rev Immunol 1995; 13: 399-415.
19. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sa USA 1993; 90: 3539-3543.
20. Middle JG, Embleton MJ. Naturally arising tumors of the inbred WAB/Not rat strain. II. Immunogenicity of transplanted tumors. J Natl Cancer Inst 1981; 67: 637-643.
21. Vieweg J et al. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 1994; 54: 1760-1765.
22. Moody DB et al. Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo. Prostate 1994; 24: 244-251.
23. Sanda MG et al Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994; 151: 622-628.
24. Yoshimura I et al. Cytokine mediated immunogene therapy in rat prostate cancer model. J Urol 1996; 155: 510a (Abstr. 798).
25. Schmidt W et al. Cancer vaccines: the interleukin 2 dosage effect. Proc Natl Acad Sci USA 1995; 92: 4711-4714.
26. Peehl DM, Stamey TA. Serum-free growth of adult human prostatic epithelial cells. In vitro Cell Devel Biol 1986; 22: 82-90.
27. Vieweg J et al. Gene transfer into primary human prostate cancer cell suspensions without further ex vivo culture. J Urol 1996; 155: 342a (Abstr. 127).
28. Vieweg J et al. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res 1995; 55: 2366-2372.
29. Zatloukal K et al. Elicitation of a systemic and protective antimelanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters. J Immunol 1995; 154: 3406-3419.
30. Dalgleish AG, Souberbielle BE. The development of therapeutic vaccines for the management of malignant melanoma. In: Leigh IM, Newton Bishop JA, Kripke ML (eds). Cancer Surveys: Skin Cancer, Vol 26, Cold Spring Harbor Laboratory Press: New York, 1996, pp 289-319.
31. Knight BC et al. Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine. Melanoma Res 1996; 6: 299-306.
32. Tjoa B et al. In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy. Prostate 1995; 27: 63-69.
33. Tjoa B et al. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate 1996; 28: 65-69.
34. Uemura H et al. Generation of anti-idiotype antibodies related to PSA: possible tools for treatment of prostate cancer. J Urol 1995; 153: 380a (Abstr. 607).
35. Riegman PH et al. The prostate-specific antigen gene and the human glandular kallikrein-1 gene are tandemly located on chromosome 19. FEBS Lett 1989; 247: 123-126.
36. Riegman PH et al. Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene. Biochem Biophys Res Commun 1989; 159: 95-102.
37. Riegman PH et al. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol 1991; 5: 1921-1930.
38. Pang S et al. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum Gene Ther 1995; 6: 1417-1426.
39. Franklin J et al. Prostate specific gene therapy using a novel PSA promoter: in vivo studies. J Urol 1996; 155: 436a (Abstr. 503).
40. Israeli RS et al. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993; 53: 227-230.
41. Israeli RS et al. Expression of the prostate-specific membrane antigen. Cancer Res 1994; 54: 1807-1811.
42. Isaacs WB et al. Molecular biology of prostate cancer. Semin Oncol 1994; 21: 514-521.
43. Carter BS et al. Allelic loss of chromosomes 16q and l0q in human prostate cancer. Proc Natl Acad Sci USA 1990; 87: 8751-8755.
44. Collins VP et al. Molecular genetics and human prostatic carcinoma. Acta Oncologica 1991; 30: 181-185.
45. Bergerheim US et al. Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma. Genes Chromos Cancer 1991; 3: 215-220.
46. Kunimi K et al. Allelotyping of human prostatic adenocarcinoma. Genomics 1991; 11: 530-536.
47. Vocke CD et al. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p 12-21. Cancer Res 1996; 56: 2411-2416.
48. Trybus TM et al. Distinct areas of allelic loss on chromosomal regions 10p and l0q in human prostate cancer. Cancer Res 1996; 56: 2263-2267.
49. Reddy EP et al. A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 1982; 300: 149-152
50. Carter BS, Epstein JI, Isaacs WB. ras Gene mutations in human prostate cancer. Cancer Res 1990; 50: 6830-6832.
51. Gumerlock PH et al. Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res 1991; 51: 1632-1637.
52. Moul JW et al. Infrequent RAS oncogene mutations in human prostate cancer. Prostate 1992; 20: 327-338.
53. Konishi N et al. K-ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men. Cancer 1992; 69: 2293-2299.
54. Anwar K et al. Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Res 1992; 52: 5991-5996.
55. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266: 1821-1828.
56. Isaacs WB et al. Genetic alterations in prostate cancer. Cold Spring Harbor Symp Quant Biol 1994; 59: 653-659.
57. Voeller HJ et al. p53 Oncogene mutations in human prostate cancer specimens. J Urol 1994; 151: 492-195.
58. Chi SG et al. p53 In prostate cancer: frequent expressed transition mutations. J Natl Cancer Just 1994; 86: 926-933.
59. Dinjens WN et al. Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int J Cancer 1994; 56: 630-633.
60. Carroll AG et al. p53 Oncogene mutations in three human prostate cancer cell lines. Prostate 1993; 23: 123-134.
61. Isaacs WB, Carter BS, Ewing CM. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 1991; 51: 4716-4720.
62. Yang C et al. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 1995; 55: 4210-4213.
63. Sehgal I et al. Adenovirus-mediated p53 gene transfer in experimental prostate cancer. J Urol 1995; 153: 309a (Abstr. 321).
64. Bookstein R et al. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci USA 1990; 87: 7762-7766.
65. Bookstein R et al. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 1990; 247: 712-715.
66. Brooks JD, Bova GS, Isaacs WB. Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate 1995; 26: 35-39.
67. Gotoh A et al. Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 and pl6) in human prostate cancers. J Urol 1996; 155: 353a (Abstr. 172).
68. Eastham JA et al. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 1995; 55: 5151-5155.
69. Umbas R et al. Expression of the cellular adhesion molecule Ecadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992; 52: 5104-5109.
70. Umbas R et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994; 54: 3929-3933.
71. Kleinerman DI et al. Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: implication as a tumor suppressor. Cancer Res 1995; 55: 1215-1220.
72. Morton RA et al. Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells. Cancer Res 1993; 53: 3585-3590.
73. Hsieh JT et al. Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches. Cancer Res 1995; 55: 190-197.
74. Kleinerman DI et al. Application of a tumor suppressor (CCAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: a preclinical study. Cancer Res 1995; 55: 2831-2836.
75. Tilley WD et al. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 1990; 50: 5382-5386.
76. Yuan S et al. Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res 1993; 53: 1304-1311. (Erratum Cancer Res 1995; 55: 719).
77. Carter G, Lemoine NR. Antisense technology for cancer therapy: does it make sense? Br J Cancer 1993; 67: 869-876.
78. Hockenbery D el al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-336.
79. McDonnell TJ el al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgenindependent prostate cancer. Cancer Res 1992; 52: 6940-6944.
80. Steiner MS et al. Gene therapy for the treatment of advanced prostate cancer by in vivo transduction with prostate targeted retroviral vectors expressing antisense c-myc RNA J Urol 1996; 155: 340a (Abstr. 118).
81. Dorai T, Olsson CA, Buttyan R Cleavage of the mRNA for the proto-oncogene bcl-2 by a hammerhead ribozyme. J Urol 1996; 155: 339a (Abstr. 115).
82. Fyfe JA et al. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J Biol Chem 1978; 253: 8721-8727.
83. Oliver S, Bubley G, Crumpacker C. Inhibition of HSV-transformed murine cells by nucleoside analogs, 2′-NDG and 2′-nor- cGMP: mechanisms of inhibition and reversal by exogenous nucleosides. Virology 1985; 145: 84-93.
84. Eastham JA et al. Prostate cancer gene therapy, herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther 1996 7: 515-523.
85. Freeman SM et al. The "bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
86. Vile RG et al. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994; 54: 6228-6234.
87. Denmeade SR, Isaacs JT. Activation of programmed (apoptotic) cell death for the treatment of prostate cancer. In: August JT, Anders MW, Murad F, Coyle JT (eds). Advances in Pharmacology, Vol 35. Academic Press: London, 1996, pp 281-306.